Biogen Pharmachem Industries Sets Record Date for 1:6 Bonus Share Issuance

1 min read     Updated on 01 Apr 2026, 01:52 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Biogen Pharmachem Industries Limited has set May 15, 2026, as the record date for its 1:6 bonus share issuance, where shareholders will receive 1 new equity share of Rs.1/- for every 6 existing shares. The proposal requires shareholder approval via postal ballot and e-voting, with the company maintaining full regulatory compliance under SEBI LODR requirements.

powered bylight_fuzz_icon
36577344

*this image is generated using AI for illustrative purposes only.

Biogen Pharmachem Industries Limited has announced the record date for its upcoming bonus share issuance, marking a significant corporate action for existing shareholders. The company has set Friday, May 15, 2026, as the crucial date for determining shareholder eligibility for the proposed bonus equity shares.

Bonus Share Details

The company has proposed issuing bonus shares in an attractive 1:6 ratio, providing substantial value to existing shareholders. Under this arrangement, eligible shareholders will receive 1 new equity share of Rs.1/- each for every 6 existing equity shares of Rs.1/- each that are fully paid up.

Parameter: Details
Record Date: Friday, May 15, 2026
Bonus Ratio: 1:6
New Share Value: Rs.1/- each
Existing Share Value: Rs.1/- each
Share Status: Fully paid up

Regulatory Compliance

The announcement has been made in compliance with Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally communicated this information to BSE Limited, where its shares are listed under scrip code 531752 and scrip ID BIOGEN.

Shareholder Approval Process

The bonus share issuance remains subject to shareholder approval, which the company is obtaining through postal ballot including e-voting facilities. This process ensures compliance with applicable laws and regulations while providing convenient voting options for shareholders.

Corporate Communication

The notification was signed by Kelash Bunkar, Wholetime Director with DIN 10911360, on April 1, 2026. The company has indicated that this information will also be made available on its official website at www.biogenpharma.bar for broader accessibility to stakeholders.

Company Information

Biogen Pharmachem Industries Limited operates from its registered office located at Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001. The company maintains communication through its official email biogenpharmachem@gmail.com and continues to fulfill its disclosure obligations as a listed entity.

Historical Stock Returns for Biogen Pharmachem

1 Day5 Days1 Month6 Months1 Year5 Years
-3.33%+11.54%-13.43%-30.95%-40.82%+163.64%

What impact will the 1:6 bonus share issuance have on Biogen Pharmachem's stock price and trading liquidity post-implementation?

How might this bonus share announcement influence investor sentiment toward other pharmaceutical companies in similar market segments?

What are the potential outcomes if shareholders reject the bonus share proposal during the postal ballot voting process?

Biogen Pharmachem Announces Postal Ballot for 1:6 Bonus Share Issue and Capital Increase

3 min read     Updated on 27 Mar 2026, 10:01 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Biogen Pharmachem Industries Limited has issued a comprehensive postal ballot notice for shareholder voting on major corporate actions including a 1:6 bonus share issue creating 15,04,33,833 new shares, authorized capital increase from Rs. 91,00,00,000 to Rs. 1,08,00,00,000, and appointment of M/s. Goenka Mehta & Associates as statutory auditors. The e-voting period runs from March 27 to April 25, 2026, with results expected by April 27, 2026.

powered bylight_fuzz_icon
35842213

*this image is generated using AI for illustrative purposes only.

Biogen Pharmachem Industries Limited has issued an official postal ballot notice for shareholder voting on major corporate actions, including a 1:6 bonus share issue and significant capital structure changes. The company has set a comprehensive voting timeline with the e-voting period scheduled from March 27 to April 25, 2026.

Postal Ballot Timeline and Process

The company has established a detailed calendar for the postal ballot process, with all key dates clearly defined for shareholder participation.

Event: Date & Time
Cut-off Date: Friday, March 20, 2026
E-Voting Commencement: Friday, March 27, 2026 at 9:00 AM
E-Voting Closure: Saturday, April 25, 2026 at 5:00 PM
Scrutinizer Report Submission: On or before Monday, April 27, 2026
Result Declaration: On or before Monday, April 27, 2026

Bonus Share Issuance Details

The board has recommended issuing fully paid-up bonus shares in a 1:6 ratio, providing shareholders with 1 new equity share for every 6 existing shares held. The bonus issue will create approximately 15,04,33,833 new equity shares of Rs. 1 each, funded through the company's securities premium account.

Parameter: Details
Bonus Ratio: 1:6 (1 share for every 6 held)
New Shares: 15,04,33,833 equity shares
Face Value: Rs. 1 per share
Funding Source: Securities Premium Account
Amount Required: Rs. 15,04,33,833
Available Premium: Rs. 17,00,00,000

Capital Structure Changes

The board approved increasing the company's authorized share capital substantially to accommodate future growth and the bonus issue.

Capital Structure: Pre-Bonus Post-Bonus
Authorized Capital: Rs. 91,00,00,000 Rs. 1,08,00,00,000
Paid-up Capital: Rs. 90,26,03,000 Rs. 1,05,30,36,833
Number of Shares: 90,26,03,000 1,05,30,36,833

Statutory Auditor Appointment

The postal ballot includes approval for appointing M/s. Goenka Mehta & Associates Chartered Accountants, Rajkot as statutory auditors to fill the casual vacancy. M/s. Rishi Sekhri & Associates Chartered Accountants resigned from their position due to significant medical conditions, with the resignation taking effect from February 9, 2026.

Auditor Transition: Details
Outgoing Auditor: M/s. Rishi Sekhri & Associates
Resignation Date: February 9, 2026
Reason: Significant medical conditions
New Auditor: M/s. Goenka Mehta & Associates
Appointment Date: February 11, 2026
Location: Rajkot
Firm Registration: 129445W

E-Voting Process and Shareholder Rights

The company will conduct the postal ballot exclusively through electronic voting via NSDL's e-voting platform. Shareholders whose names appear in the register of members or beneficial owners list as on the cut-off date of March 20, 2026, are eligible to participate in the voting process.

The voting covers three ordinary resolutions: approval for bonus share issue in 1:6 ratio, increase in authorized share capital from Rs. 91,00,00,000 to Rs. 1,08,00,00,000 with consequent alteration of Clause V of the Memorandum of Association, and appointment of statutory auditors.

Regulatory Compliance and Documentation

M/s. Daksha Negi & Associates, Practicing Company Secretaries, has been appointed as the scrutinizer for conducting the voting process. The company has ensured full compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable regulations.

The bonus shares, once allotted, will rank pari-passu with existing equity shares and carry identical rights. Shareholders will be entitled to participate in dividends and other corporate actions declared after the new shares are allotted. The company maintains adequate reserves with securities premium available totaling Rs. 17,00,00,000, providing sufficient coverage for the required Rs. 15,04,33,833 for bonus implementation.

Historical Stock Returns for Biogen Pharmachem

1 Day5 Days1 Month6 Months1 Year5 Years
-3.33%+11.54%-13.43%-30.95%-40.82%+163.64%

How might the 1:6 bonus share issue impact Biogen Pharmachem's stock liquidity and trading volumes in the coming quarters?

What strategic initiatives or expansion plans could the company be preparing for with the substantial increase in authorized capital to Rs. 108 crores?

Will the change in statutory auditors from Delhi-based to Rajkot-based firm signal any shifts in the company's operational focus or governance approach?

More News on Biogen Pharmachem

1 Year Returns:-40.82%